Sugi Predict

Sugi Predict / Compounds / SCHEMBL608203

SCHEMBL608203

SCHEMBL608203

CS(=O)(=O)O[C@H]1CCN(Cc2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ RECQL P46063 1/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.51
▸ ACHE P22303 2/20 0.50
▸ HTR2A P28223 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.49
▸ BCHE P06276 4/20 0.48
▸ DRD2 P14416 1/20 0.48
▸ BACE1 P56817 1/20 0.47
▸ MAOB P27338 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273941 1.00 SMN1; SMN2 (0.51) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL608204 1.00 SMN1; SMN2 (0.51) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL6279418 0.94 ALDH1A1 (0.57) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL28497475 0.92 BCHE (0.58) SMN1; SMN2RECQLHRH3ACHEALDH1A1
SCHEMBL19209909 0.92 BCHE (0.58) SMN1; SMN2RECQLHRH3ACHEALDH1A1
SCHEMBL5745231 0.92 BCHE (0.58) SMN1; SMN2RECQLHRH3ACHEALDH1A1
SCHEMBL5744278 0.91 HRH3 (0.59) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL5746137 0.88 FUCA1 (0.47) SMN1; SMN2RECQLHRH3ACHEHTR2A
SCHEMBL3890353 0.86 HRH3 (0.55) HRH3ACHEBCHEBACE1
SCHEMBL5184838 0.85 HRH3 (0.44) SMN1; SMN2RECQLHRH3ALDH1A1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
EP-1693364-B1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI SANKYO CO LTD (JP) 2015-05-20 — — EP disclosed
EP-1963304-B2 ISOQUINOLINE DERIVATIVES MSD OSS BV (NL) 2015-05-13 — — EP disclosed
US-8946422-B2 8-methoxy-9H-isothiazolo[5,4-B]quinoline-3,4-diones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2015-02-03 — — US disclosed
EP-2616071-A2 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-24 — — EP disclosed
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2013-07-04 — — US disclosed
WO-2012037299-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-03-22 — — WO disclosed
US-20120040959-A1 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS, INC. (US) 2012-02-16 — — US disclosed
US-8044204-B2 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2011-10-25 — — US disclosed
US-8044204-B2 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2011-10-25 — — US disclosed
US-6281243-B1 ANTIDEPRESSANTS, ANTISEROTONINE AGENT AKZO NOBEL N.V. (NL) 2001-08-28 — — US disclosed
US-6005119-A Process for preparing pyrrolidine derivatives KANEKA CORPORATION (JP) 1999-12-21 — — US disclosed
WO-1999043647-A1 DERIVATIVES OF AZETIDINE AND PYRROLIDINE AKZO NOBEL N.V. (NL) 1999-09-02 — — WO disclosed
EP-0900787-A1 PROCESS FOR PREPARING PYRROLIDINE DERIVATIVES KANEKA CORPORATION (JP) 1999-03-10 — — EP disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 — — EP disclosed
EP-0863136-A1 Derivatives of azetidine and pyrrolidine Akzo Nobel N.V. (NL) 1998-09-09 — — EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 — — WO disclosed
US-5466828-A Chiral 3-cyano-1-substituted-pyrrolidines WARNER-LAMBERT COMPANY (US) 1995-11-14 — — US disclosed
WO-1995001962-A1 PROCESS FOR THE PREPARATION OF CHIRAL 3-(1-AMINO-1,1-BISALKYLMETHYL)-1-SUBSTITUTED-PYRROLIDINES WARNER-LAMBERT COMPANY (US) 1995-01-19 — — WO disclosed
US-5347017-A Process for chiral 3-(1-amino-1,1-bisalkylmethyl)-1-substituted-pyrrolidines WARNER-LAMBERT COMPANY (US) 1994-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 SMN1; SMN2 4821/4885RECQL 4112/4885HRH3 4381/4885
US-20120040959-A1 8-METHOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS TOP1, TOP2B, DNA2 SMN1; SMN2 4142/4885RECQL 5/4885HRH3 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.